ESR1 and breast cancer: A randomized phase III trial comparing adjuvant S-1 plus standard hormonal therapy to standard hormonal therapy alone in ER-positive and HER2-negative primary breast cancer with intermediate and/or high risk of recurrence is now ongoing in Japan (POTENT: Postoperative Therapy with Endocrine and TS-1, UMIN000003969).